EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery

Aaron M Bender iD, Lauren C Parr, William B Livingston iD, Craig W Lindsley iD, W David Merryman

Journal of Medicinal Chemistry · 24.08.2023 · 66 (16) · 11027-11039

DOI: 10.1021/acs.jmedchem.3c01178 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.08.2023. Verfasst von Aaron M Bender und 4 weiteren Autor:innen. Beteiligte Einrichtung: Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT2B, Heart Valve Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardiotoxicity associated with des-ethyl-dexfenfluramine (norDF) and related agonists of the serotonin receptor 2B (5-HT2B) has solidified the receptor's place as an "antitarget" in drug discovery. Conversely, a growing body of evidence has highlighted the utility of 5-HT2B antagonists for the treatment of pulmonary arterial hypertension (PAH), valvular heart disease (VHD), and related cardiopathies. In this Perspective, we summarize the link between the clinical failure of fenfluramine-phentermine (fen-phen) and the subsequent research on the role of 5-HT2B in disease progression, as well as the development of drug-like and receptor subtype-selective 5-HT2B antagonists. Such agents represent a promising class for the treatment of PAH and VHD, but their utility has been historically understudied due to the clinical disasters associated with 5-HT2B. Herein, it is our aim to examine the current state of 5-HT2B drug discovery, with an emphasis on the receptor's role in the central nervous system (CNS) versus the periphery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Serotonin, 5-HT2BHeart Valve DiseasesHumansSerotoninFenfluramineDrug Discovery

Substanzen

Receptor, Serotonin, 5-HT2BSerotoninFenfluramine

Autor:innen und Institutionen

  • Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240, United States.
  • Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.

ORCID-Profile: Aaron M Bender, William B Livingston, Craig W Lindsley

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • NICHD NIH HHS
  • Vanderbilt University
  • National Cancer Institute
  • Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University
  • National Institutes of Health

Zitieren

APA

Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C. W., & Merryman, W. D. (2023). 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery. Journal of Medicinal Chemistry, 66(16), 11027-11039. https://doi.org/10.1021/acs.jmedchem.3c01178

Vancouver

Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD. 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery. Journal of Medicinal Chemistry. 2023;66(16):11027-11039. doi:10.1021/acs.jmedchem.3c01178

BibTeX
@article{Bender2023,
  author = {Bender, Aaron M and Parr, Lauren C and Livingston, William B and Lindsley, Craig W and Merryman, W David},
  title = {2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {16},
  pages = {11027--11039},
  doi = {10.1021/acs.jmedchem.3c01178}
}
Kostenlos starten →